ChemoMetec A/S

CPSE:CHEMM Stock Report

Market Cap: DKK 8.4b

ChemoMetec Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Martin Behrens

Chief executive officer

DKK 2.9m

Total compensation

CEO salary percentage30.0%
CEO tenureless than a year
CEO ownership0.02%
Management average tenureless than a year
Board average tenure3.7yrs

Recent management updates

Recent updates

What Is ChemoMetec A/S's (CPH:CHEMM) Share Price Doing?

Dec 12
What Is ChemoMetec A/S's (CPH:CHEMM) Share Price Doing?

ChemoMetec A/S (CPH:CHEMM) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected

Nov 09
ChemoMetec A/S (CPH:CHEMM) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected

We Think That There Are More Issues For ChemoMetec (CPH:CHEMM) Than Just Sluggish Earnings

Sep 18
We Think That There Are More Issues For ChemoMetec (CPH:CHEMM) Than Just Sluggish Earnings

What ChemoMetec A/S' (CPH:CHEMM) 27% Share Price Gain Is Not Telling You

Jul 29
What ChemoMetec A/S' (CPH:CHEMM) 27% Share Price Gain Is Not Telling You

Earnings Not Telling The Story For ChemoMetec A/S (CPH:CHEMM) After Shares Rise 27%

Jul 29
Earnings Not Telling The Story For ChemoMetec A/S (CPH:CHEMM) After Shares Rise 27%

What Is ChemoMetec A/S's (CPH:CHEMM) Share Price Doing?

Jul 03
What Is ChemoMetec A/S's (CPH:CHEMM) Share Price Doing?

Some Confidence Is Lacking In ChemoMetec A/S (CPH:CHEMM) As Shares Slide 32%

Apr 15
Some Confidence Is Lacking In ChemoMetec A/S (CPH:CHEMM) As Shares Slide 32%

What ChemoMetec A/S' (CPH:CHEMM) 30% Share Price Gain Is Not Telling You

Mar 01
What ChemoMetec A/S' (CPH:CHEMM) 30% Share Price Gain Is Not Telling You

What Does ChemoMetec A/S's (CPH:CHEMM) Share Price Indicate?

Mar 01
What Does ChemoMetec A/S's (CPH:CHEMM) Share Price Indicate?

Earnings Beat: ChemoMetec A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 08
Earnings Beat: ChemoMetec A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Unpleasant Surprises Could Be In Store For ChemoMetec A/S' (CPH:CHEMM) Shares

Dec 21
Unpleasant Surprises Could Be In Store For ChemoMetec A/S' (CPH:CHEMM) Shares

Is It Time To Consider Buying ChemoMetec A/S (CPH:CHEMM)?

Nov 15
Is It Time To Consider Buying ChemoMetec A/S (CPH:CHEMM)?

ChemoMetec A/S (CPH:CHEMM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Sep 17
ChemoMetec A/S (CPH:CHEMM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

A Look At The Intrinsic Value Of ChemoMetec A/S (CPH:CHEMM)

Sep 15
A Look At The Intrinsic Value Of ChemoMetec A/S (CPH:CHEMM)

At kr.467, Is ChemoMetec A/S (CPH:CHEMM) Worth Looking At Closely?

Jun 20
At kr.467, Is ChemoMetec A/S (CPH:CHEMM) Worth Looking At Closely?

With EPS Growth And More, ChemoMetec (CPH:CHEMM) Makes An Interesting Case

Jun 01
With EPS Growth And More, ChemoMetec (CPH:CHEMM) Makes An Interesting Case

Here's Why ChemoMetec (CPH:CHEMM) Has Caught The Eye Of Investors

Jan 24
Here's Why ChemoMetec (CPH:CHEMM) Has Caught The Eye Of Investors

If EPS Growth Is Important To You, ChemoMetec (CPH:CHEMM) Presents An Opportunity

Oct 26
If EPS Growth Is Important To You, ChemoMetec (CPH:CHEMM) Presents An Opportunity

Is It Time To Consider Buying ChemoMetec A/S (CPH:CHEMM)?

Oct 05
Is It Time To Consider Buying ChemoMetec A/S (CPH:CHEMM)?

Does ChemoMetec (CPH:CHEMM) Deserve A Spot On Your Watchlist?

Jul 18
Does ChemoMetec (CPH:CHEMM) Deserve A Spot On Your Watchlist?

Here's Why I Think ChemoMetec (CPH:CHEMM) Is An Interesting Stock

Mar 27
Here's Why I Think ChemoMetec (CPH:CHEMM) Is An Interesting Stock

CEO Compensation Analysis

How has Martin Behrens's remuneration changed compared to ChemoMetec's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024DKK 3mDKK 877k

DKK 136m

Compensation vs Market: Martin's total compensation ($USD410.17K) is below average for companies of similar size in the Danish market ($USD1.42M).

Compensation vs Earnings: Insufficient data to compare Martin's compensation with company performance.

CEO

Martin Behrens (32 yo)

less than a year

Tenure

DKK 2,923,041

Compensation

Mr. Martin Helbo Behrens serves as CEO at ChemoMetec A/S since March 13, 2024. He is Chief Operating Officer of ChemoMetec A/S from December 2023. He was Vice Chief Operating Officer of ChemoMetec A/S from...

Leadership Team

NamePositionTenureCompensationOwnership
Martin Behrens
CEO & COOless than a yearDKK 2.92m0.019%
DKK 1.6m
Hans Glensbjerg
Deputy Chairman & Senior Advisorno dataDKK 150.00k0.31%
DKK 26.2m
Kim Nicolajsen
Chief Financial Officerless than a yearno datano data
Christopher Runchel
Chief Sales Officerno datano datano data
Marta Planaguma
Chief Marketing & Strategy Officerless than a yearno datano data
Lisbet Helles
Head of Marketingless than a yearno datano data
Søren Kjærulff
Head of R&Dno datano datano data
Bo Nielsen
Chief R&D Officer and Physicist & Project Managerless than a yearno datano data

1.0yrs

Average Tenure

44yo

Average Age

Experienced Management: CHEMM's management team is not considered experienced ( 1 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Hans Glensbjerg
Deputy Chairman & Senior Advisorno dataDKK 150.00k0.31%
DKK 26.2m
Peter Reich
Independent Director10.2yrsDKK 100.00k0.0083%
DKK 700.2k
Kristine Faerch
Independent Director4.2yrsDKK 100.00k0.00086%
DKK 72.3k
Niels Thestrup
Chairman3.2yrsDKK 360.00k0.011%
DKK 941.4k
Betina Hagerup
Independent Director3.2yrsDKK 100.00k0.0017%
DKK 141.2k

3.7yrs

Average Tenure

62yo

Average Age

Experienced Board: CHEMM's board of directors are considered experienced (3.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 06:51
End of Day Share Price 2024/12/18 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ChemoMetec A/S is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kallum TitchmarshBofA Global Research
null nullDanske Bank
Simon LarssonDanske Bank